

BRISTOL

Current Perspectives in Haematological Malignancies 2016

3rd November, *Hilton Doubletree Hotel, Redcliffe Way, Bristol*

10:30am – 5.30pm

**Updates and hot topics in the changing face of the NHS:
Is the current model of drug development affordable and attainable?**

**Chairs: Professor Adrian Newland, Barts Health NHS Trust
Dr Stephen Robinson, University Hospitals of Bristol**

Speakers include:

Dr Andrew McMillan	<i>Nottingham City Hospital</i>
Professor Graham Jackson	<i>Royal Victoria Infirmary, Newcastle</i>
Dr Karthik Ramasamy	<i>John Radcliffe Hospital, Oxford</i>
Professor Simon Rule	<i>University Hospital of Plymouth</i>
Dr George Follows	<i>Addenbrooke's Hospital, Cambridge</i>
Dr Mike Dennis	<i>Christie Hospital, Manchester</i>
Professor Tim Illidge	<i>Christie Hospital, Manchester</i>
Professor Emma Morris	<i>University College London</i>

- ❖ Myeloma, upfront treatment of newly diagnosed patients - Graham Jackson
- ❖ Myeloma, relapsed refractory – are combinations the future? - Karthik Ramasamy
- ❖ ALL update– Andrew McMillan
- ❖ New agents in CLL – what drug when? - George Follows
- ❖ AML update - Mike Dennis
- ❖ Novel agents in lymphoma where are we going? - Simon Rule
- ❖ Future of immunotherapy: what are the check-point inhibitors, how do they work? – Tim Illidge
- ❖ What is the role of radiotherapy, interesting case studies - Tim Illidge
- ❖ Is chemotherapy standard of care for lymphoma? - Andrew McMillan
- ❖ Haematological Malignancies - T-Cell Therapies; CAR-T cells & TCR gene-modified T cells – Emma Morris

Registration: £60.00 (plus VAT)

Register online at www.hartleytaylor.co.uk or contact Kristy on 01565 621967 or email kristy@hartleytaylor.co.uk
For sponsorship opportunities, please contact Kristy on Kristy@hartleytaylor.co.uk